TY - JOUR
T1 - Patients with ICD-10-CM codes for Naegleriasis in U.S. hospitals, 2016-2024
T2 - A retrospective analysis of administrative data
AU - Wilkins, Thad
AU - Harris, Alyssa
AU - Cagle, Will
AU - Vikram, Pravin
AU - Coule, Phillip
AU - Vazquez, Jose
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/10
Y1 - 2025/10
N2 - Objectives: Naegleria fowleri is a free-living amoeba that causes primary amoebic meningoencephalitis (PAM), a rare and nearly always fatal infection. Other free-living amoebae may cause similar presentations. This study characterizes demographic features, clinical outcomes, and antimicrobial use among patients coded with naegleriasis in a large administrative database. Methods: A retrospective analysis was conducted using the Vizient® Clinical Database, which includes discharge-level data from over 500 U.S. hospitals. Patients discharged between January 2016 and February 2024 with ICD-10-CM code B60.2 (naegleriasis) were identified. Demographics, inpatient mortality, antimicrobial use, and discharge disposition were summarized using descriptive statistics. Results: Twenty-two patients were identified. The mean age was 37 years; 73% were adults. In-hospital mortality was 50%. Survivors had longer hospital stays than nonsurvivors. Amphotericin B and fluconazole were the most used antimicrobials. Diagnostic confirmation of PAM was unavailable, and additional clinical details were not accessible. Conclusions: Patients coded with naegleriasis were mostly adults and had lower mortality than expected for confirmed PAM. The 50% survival rate suggests possible misclassification. These findings are hypothesis-generating and highlight the need for case-based studies with laboratory confirmation to clarify epidemiologic trends.
AB - Objectives: Naegleria fowleri is a free-living amoeba that causes primary amoebic meningoencephalitis (PAM), a rare and nearly always fatal infection. Other free-living amoebae may cause similar presentations. This study characterizes demographic features, clinical outcomes, and antimicrobial use among patients coded with naegleriasis in a large administrative database. Methods: A retrospective analysis was conducted using the Vizient® Clinical Database, which includes discharge-level data from over 500 U.S. hospitals. Patients discharged between January 2016 and February 2024 with ICD-10-CM code B60.2 (naegleriasis) were identified. Demographics, inpatient mortality, antimicrobial use, and discharge disposition were summarized using descriptive statistics. Results: Twenty-two patients were identified. The mean age was 37 years; 73% were adults. In-hospital mortality was 50%. Survivors had longer hospital stays than nonsurvivors. Amphotericin B and fluconazole were the most used antimicrobials. Diagnostic confirmation of PAM was unavailable, and additional clinical details were not accessible. Conclusions: Patients coded with naegleriasis were mostly adults and had lower mortality than expected for confirmed PAM. The 50% survival rate suggests possible misclassification. These findings are hypothesis-generating and highlight the need for case-based studies with laboratory confirmation to clarify epidemiologic trends.
KW - Administrative data
KW - Central Nervous System Protozoal Infections
KW - Epidemiology
KW - International Classification of Diseases
KW - Naegleria fowleri
UR - https://www.scopus.com/pages/publications/105013115953
UR - https://www.scopus.com/pages/publications/105013115953#tab=citedBy
U2 - 10.1016/j.ijid.2025.107999
DO - 10.1016/j.ijid.2025.107999
M3 - Article
C2 - 40730264
AN - SCOPUS:105013115953
SN - 1201-9712
VL - 159
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
M1 - 107999
ER -